Taken together, these data suggest that both P2X7-targeting biologics, the blocking 13A7-hcAbs as well as the potentiating 14D5-dimHLE, can improve tumor control in combination with oxaliplatin chemotherapy, although with different mechanisms of action. The gene discussed is P2RX7; the disease is neoplasm.